Achievement rates of japan atherosclerosis society guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin

Cardiovascular Therapeutics

Volumn 32, Issue 3, 2014, Pages 97-104

  Shioji, Keisuke ^a   Izuhara, Masayasu ^a   Mitsuoka, Hirokazu ^a   Uegaito, Takashi ^a   Matsuda, Mitsuo ^a  

^a Kishiwada City Hospital   (Japan)

Author keywords

Atorvastatin; Cholesterol lowering drugs; Drug therapy; Japan; LDL cholesterol; Rosuvastatin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; BIOLOGICAL MARKER; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; COMPLICATION; DYSLIPIDEMIAS; JAPAN; MEDICAL SOCIETY; MIDDLE AGED; PRACTICE GUIDELINE; RISK FACTOR; TIME;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DRUG SUBSTITUTION; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; GUIDELINE ADHERENCE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINES; PYRROLES; RISK FACTORS; SOCIETIES, MEDICAL; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899094747     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12066     Document Type: Article

References (28)

1. Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006;368:1155-1163.
2. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infection 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
3. Ray KK, Cannon CP, Cairns R, et al. PROVE IT-TIMI 22 Investigators. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1417-1424.
4. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
5. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007;14:45-50.
6. Teramoto T, Kashiwagi A, Mabuchi H. Status of lipid-lowering therapy prescribed based on recommendation in the 2002 report of the Japan Atherosclerosis Society guideline for diagnosis and treatment of hyperlipidemia in Japanese adults: A study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res 2005;66:80-95.
7. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003;91:33-41.
8. Jones PH, Davidson MH, Stein EA, et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-160.
9. Schuster H, Barter PJ, Stender S, et al.; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004;147:705-713.
10. Kurabayashi M, Yamazaki T. Superior benefit of aggressive lipid-lowering therapy for high-risk patients using statins: The SUBARU study-more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb 2008;15:314-323.
11. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-1080.
12. Stalenhoef AFH, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W. A comparative study with rosuvastatin in subjects with metabolic syndrome: Results of the COMETS study. Eur Heart J 2005;26:2664-2672.
13. Arima H, Kubo M, Yonemoto K, et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: The Hisayama study. Arterioscler Thromb Vasc Biol 2008;28:1385-1391.
14. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006;114:281-288.
15. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 2008;52:626-632.
16. Kim K, Birmingham BK, Azumaya CT, Zalikoski J, Schneck D. Increased systemic exposure to rosuvastatin in Asian subjects residing in the United Staes compared with Caucasian subjects. [Poster] Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 2-5 April 2008, Orlando, Florida. http://wcct.com/wp-content/uploads/2010/02/LB1-ASCPT08-poster-14-03-08.pdf
17. Hu M, Lui SS, Ko GT, Tomlinson B. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. Int J Cardiol 2013;168:3071-3073.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
19. Arai H, Yamamoto A, Matsuzawa Y, et al. Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb 2005;12:98-106.
20. Okamura T, Kadowaki T, Hayakawa T, Kita Y, Okayama A, Ueshima H. What cause of mortality can we predict by cholesterol screening in the Japanese general population? J Intern Med 2003;253:169-180.
21. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
22. Sattar N, Murray HM, McConnachie A, et al.; PROSPER Study Group. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007;115:981-989.
23. Wakugawa Y, Kiyohara Y, Tanizaki Y, et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: The Hisayama Study. Stroke 2006;37:27-32.
24. Saito Y, Goto Y, Dane A, Strutt K, Raza A. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2003;10:329-336.
25. Mabuchi H, Nohara A, Higashikata T, et al. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2004;11:152-158.
26. Saito Y, Yamada N, Shirai K, Sasaki J, Ebihara Y, Yanase T, Fox JC. Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis 2007;194:505-511.
27. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148-152.
28. Navarese EP, Szczesniak A, Kolodziejczak M, Gorny B, Kubica J, Suryapranata H. Statins and risk of new-onset diabetes mellitus: Is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs 2013; [Epub ahead of print].